UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/978,454	10/15/2001	Mark D. Erion	030727.0027.CON1	5123

23865 7590 08/29/2002

BROBECK, PHLEGER & HARRISON LLP
12390 EL CAMINO REAL
SAN DIEGO, CA 92130

EXAMINER
JONES, DAMERON LEVEST

ART UNIT	PAPER NUMBER
1616	

DATE MAILED: 08/29/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/978,454	ERION ET AL.	
	Examiner	Art Unit	
	D. L. Jones	1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *11/15/01; 1/25/02; and 2/8/02* .

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 1 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) 1 is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☒ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☒ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4 .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other:

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the following:

a. Paper No. 2, filed 11/15/01, wherein claims 2-167 were canceled; and

b. Paper No. 3, filed 1/25/02, wherein claims 5 was amended and claim 13 was added. (***Note***: *It is duly noted that Applicant is attempting to amend and add claims that were canceled in the amendment filed 11/15/01, Paper No. 2.*)

Note: Claim 1 is pending.

APPLICANT'S INVENTION

2. Applicant's invention is directed to a method of enhancing oral bioavailability of a parent drug by administering a compound of formula I as set forth in independent claim 1.

STATUTORY DOUBLE PATENTING

3. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

4. Claim 1 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of prior U.S. Patent No. 6,312,662 B1. This is a double patenting rejection.

ABSTRACT

5. The abstract of the disclosure is objected to because it exceeds 25 lines of text. Correction is required. See MPEP § 608.01(b).

SPECIFICATION

6. The disclosure is objected to because of the following informalities: a portion of the structure is missing from page 52 (line 52) and page 54 (line 1).

Appropriate correction is required.

CONTINUING DATA

7. Applicant is respectfully requested to update the continuing data appearing on page 1, first paragraph, of the specification.

COMMENTS/NOTES

8. Applicant is respectfully suggested to insert the term 'containing' in claim 1, line 9, after the term 'optionally'.

9. It is noted that a prior art rejection has not been made over claim 1. Thus, claim 1 is allowable over the prior art; however, Applicant MUST address and overcome the double patenting rejection, update the continuing data, amend the abstract, and submit clean copies of the structures on pages 52 and 54. In particular, the claims are distinguished over the prior art of record because it neither anticipates nor renders obvious a method of enhancing oral bioavailability of a parent drug by administering a prodrug of formula I as set forth in independent claim 1.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (703) 308-4640. The examiner can normally be reached on Mon.-Fri. (alternate Mon.), 6:45 a.m. - 4:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose' Dees can be reached on (703) 308- 4628. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

D. L. Jones
Primary Examiner
Art Unit 1616

August 22, 2002

Form PTO 948 (Rev. 03/02) U.S. DEPARTMENT OF COMMERCE - Patent and Trademark Office Application No. 9/978,454

NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) filed (insert date) 10-15-01 are:

A. ☐ approved by the Draftsperson under 37 CFR 1.84 or 1.152.

B. ☑ objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. The Examiner will require submission of new, corrected drawings when necessary. Corrected drawing must be sumitted according to the instructions on the back of this notice.

1. DRAWINGS. 37 CFR 1.84(a): Acceptable categories of drawings:
   Black ink. Color.
   ___ Color drawings are not acceptable until petiton is granted. Fig(s) ___
   ___ Pencil and non black ink not permitted. Fig(s) ___
2. PHOTOGRAPHS. 37 CFR 1.84(b)
   ___ 1 full-tone set is required. Fig(s) ___
   ___ Photographs may not be mounted. 37 CFR 1.84(e)
   ___ Poor quality (half-tone). Fig(s) ___
3. TYPE OF PAPER. 37 CFR 1.84(e)
   ___ Paper not flexible, strong, white, and durable. Fig(s) ___
   ___ Erasures, alterations, overwritings, interlineations, folds, copy machine marks not accepted. Fig(s) ___
   ___ Mylar, velum paper is not acceptable (too thin). Fig(s) ___
4. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes:
   ___ 21.0 cm by 29.7 cm (DIN size A4)
   ___ 21.6 cm by 27.9 cm (8 1/2 x 11 inches)
   ___ All drawing sheets not the same size. Sheet(s) ___
   ___ Drawings sheets not an acceptable size. Fig(s) ___
5. MARGINS. 37 CFR 1.84(g): Acceptable margins:
   Top 2.5 cm Left 2.5cm Right 1.5 cm Bottom 1.0 cm SIZE: A4 Size
   Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm SIZE: 8 1/2 x 11
   Margins not acceptable. Fig(s) ___
   ___ Top (T) ___ Left (L)
   ___ Right (R) ___ Bottom (B)
6. VIEWS. 37 CFR 1.84(h)
   REMINDER: Specification may require revision to correspond to drawing changes.
   Partial views. 37 CFR 1.84(h)(2)
   ___ Brackets needed to show figure as one entity. Fig(s) ___
   ___ Views not labeled separately or properly. Fig(s) ___
   ___ Enlarged view not labeled separetely or properly. Fig(s) ___
7. SECTIONAL VIEWS. 37 CFR 1.84 (h)(3)
   ___ Hatching not indicated for sectional portions of an object. Fig(s) ___
   ___ Sectional designation should be noted with Arabic or Roman numbers. Fig(s) ___
8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i)
   ___ Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) ___
9. SCALE. 37 CFR 1.84(k)
   ___ Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction. Fig(s) ___
10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l)
   ✓ Lines, numbers & letters not uniformly thick and well defined, clean, durable, and black (poor line quality). Fig(s) 1A, 1B
11. SHADING. 37 CFR 1.84(m)
   ___ Solid black areas pale. Fig(s) ___
   ___ Solid black shading not permitted. Fig(s) ___
   ___ Shade lines, pale, rough and blurred. Fig(s) ___
12. NUMBERS, LETTERS, & REFERENCE CHARACTERS. 37 CFR 1.84(p)
   ✓ Numbers and reference characters not plain and legible. Fig(s) 1A, 1B
   ___ Figure legends are poor. Fig(s) ___
   ___ Numbers and reference characters not oriented in the same direction as the view. 37 CFR 1.84(p)(1) Fig(s) ___
   ___ English alphabet not used. 37 CFR 1.84(p)(2) Figs ___
   ___ Numbers, letters and reference characters must be at least .32 cm (1/8 inch) in height. 37 CFR 1.84(p)(3) Fig(s) ___
13. LEAD LINES. 37 CFR 1.84(q)
   ___ Lead lines cross each other. Fig(s) ___
   ___ Lead lines missing. Fig(s) ___
14. NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1.84(t)
   ___ Sheets not numbered consecutively, and in Arabic numerals beginning with number 1. Sheet(s) ___
15. NUMBERING OF VIEWS. 37 CFR 1.84(u)
   ___ Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) ___
16. CORRECTIONS. 37 CFR 1.84(w)
   ___ Corrections not made from prior PTO-948 dated ___
17. DESIGN DRAWINGS. 37 CFR 1.152
   ___ Surface shading shown not appropriate. Fig(s) ___
   ___ Solid black shading not used for color contrast. Fig(s) ___

COMMENTS

REVIEWER J. CHASE DATE 8-22-02 TELEPHONE NO. 703 305 8430

ATTACHMENT TO PAPER NO. ___

Notice of References Cited	Application/Control No. 09/978,454	Applicant(s)/Patent Under Reexamination ERION ET AL.	
	Examiner D. L. Jones	Art Unit 1616	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,312,662 B1	11-2001	Erion et al	424/9.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. D NO.	SERIAL NO.
030727.027.CON1	09/978,454
APPLICANT: ERION	
FILING DATE: 10/15/01	GROUP: ~~TBA~~ 1616

COPY OF PAPERS ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	3,018,302 A	01.23.62	Bielefeld, *et al.*	—	—	
	AB	5,658,889	08/19/97	GRUBER, *et al.*	514	43	12/14/94

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLAT YES	N
	AC	91 19721 A1	12/26/91	WO				
	AD	98 39344 A	11/09/98	WO				
	AE	98 39343 A	11/09/98	WO				
	AF	98 39342 A	11/09/98	WO				
	AG	0 180 276 A1	05/07/86	EP				
	AH	3512781 A1	04/10/85	DE				
	AI	0 353 692 B1	07.02.90	EPO				
	AJ	WO 96/01267 A	18.01.96	WO				
	AK	0 161 955 A	21.11.85	EPO				
	AL	WO 97/03679 A	06.02.97	WO				
	AM	0 338 372 A	25.10.89	EPO				
	AN	0 481 214 A	22.04.92	EPO	—	—		

EXAMINER:	DATE CONSIDERED: 8/27/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

		OTHER DOCUME... (Including Author, Title, Date, ...ent Pages, etc.)
	AO	Alexander, *et al.*, "Preparation of 9-(2- Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs," Collect. Czech, Chem Commun., 59: 1853-1869 (1994)
	AP	Amin, *et al.*,"1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic Acid as a Potent Inhibitor o Squalene Synthase," Arznemittelforschung. 46(8): 759-762 (1996)
	XA	Atiq, O.T., *et al.*, "Treatment of Unresectable Primary Liver cancer With Intrahepatic Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," *Cancer*, 69, 920-924 (1992)
	AQ	Auberson, *et al.*, "*N*-Phosphoalkyl-5-Aminomethylquinoxaline-2,3-Diones: *In Vivo* Active Ampa and NMDA(Glycine) Antagonists," Bioorg. Med. Chem. Lett., 9: 249-254 (1999)
	AR	Balthazor, *et al.* "Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observation," J. Org Chem., 45: 5425-5426 (1980)
	XB	He, *et al.*, "Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice," Chem Res. Toxicol 1998, 11, 252-259
	AS	Bespalov, *et al.*, "Prologation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats," Eur. J. Pharmacol. 351: 299-305 (1998)
	AT	Bijsterbosch, *et al.*, "Disposition of the acyclic Nucleoside Phosphonate (*S*)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl) Adenine," Antimicrobial Agents and Chemotherapy. 42(5): 1146-1150 (1998)
	AU	Bird, *et al.*, "Synthesis of Novel *N*-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," J. Med. Chem. 73: 158-169 (1994)
	AV	Brill and Landon, *et al.*, Chem Rev., 84: 577-585 (1984)
	AW	Campagne, *et al.* "Synthesis of Mixed Phosphate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," Tetrahedron Lett., 34(42): 6743-6744 (1993)

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900
COPY OF PAPERS ORIGINALLY FILED

EXAMINER:	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	AX	Campbell, "The Synthesis of Phosphonate Esthers, an Extension of the Mitsunobu Reation," J. Org. Chem. 57: 6331-6335 (1992)
	AY	Casara, *et al.*, "Synthesis of Acid Stable 5'-o-Fluorometer Phosphonates of Nucleosides," Bioorg. Med. Chem. Lett., 2(2): 145-148 (1992)
	AZ	Casteel, *et al.*, "Steric and Electronic Effects in the Aryl Phosphate to Arylphoshonate Rearrangement," Synthesis, 691-693 (1991)
	XC	Chen, *et al.*, , "Sensitization of Human Breast Cancer Cels to Cyclophosphamide and Ifosfamide by Transfer of al Liver Cytochrome P450 Gene," Cancer Research, 56, 1331-1340 (1996)
	XD	Chen and Waxman "Intratumoral Activation and Enhanced Chemotheraputic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined chemptherapy/Cancer Gene Therapy Strategy," Cancer Research, 55, 581-589 (1995)
	BA	De Lombaert, *et al.*, "N-Phosphomomethgyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors" J. Med. Chem 37: 498-511 (1994)
	BB	De Lombaert, *et al.*, "Pharmacological profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-converting enzyme," Biochem Biophys Res Commun 204: 407-412 (1994)
	BC	De Waziers, *et al.*, "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues," J. Pharm. Exp. Ther. 253: 387-394 (1990)
	BD	Dearfield, *et al.*, "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Coumpounds in L5178Y Mouse Lymphoma Cells," Mutagenisis 4: 381-393 (1989)
	BE	Desos, *et al.*, "Structure-Activity Relationships in a Series of 2(1*H*)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1*H*)-oxoquinoline-3-phosphonic Acid, a New Potent and Selectiv AMPA/Kainate Antagonist with Neuroprotective Properties," 39: 197-206 (1996)
	BF	Dickson, *et al.*, "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the α-Phosphonosulfonic Acid Moiety," J. Med. Chem. 39: 661-664 (1996)

EXAMINER: D Jones	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OTHER DOCUME (Including Author, Title, Date nt Pages, etc.)	
BG	Edmunson, *et al.*, "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of *cis*-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)
BH	Enriquez, *et al.*,"Conjugation of Aadenine Arabinoside 5'-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," Bioconjugate Chem. 6: 195-202 (1995)
BI	Farquhar, *et al.* "Biologically-Cleavable Phosphate Protective Groups: 4-Aclioxt-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," Tetrahedron Lett., 36(5): 655-658 (1995)
BJ	Farquhar, *et al.*, "Biologically Reversible Phosphate-Protective Groups," Journal of Pharmaceutical Sciences 72(3): 324-325 (1983)
BK	Farquhar, *et al.*, "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985)
BL	Farquhar, *et al.*, "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)
BM	Fiume, *et al.*,"Inhibition of Hepatitis B Virus replication By Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin," The Lancet 13-15 (1988)
BN	Freed, *et al.*, "Evidence for Acyloxymethyyl Esters of Pyridmidenc, 5'-Deoxyribonucleotides as extraceullar sources of active a5'-deozyriboinucleotides in cultured cells," Biochemical Pharmacology, 38(19): 3193-3198 (1989)
BO	Guida, *et al.*,"Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics," J. Med. Chem. 37: 1109-1114 (1994)
BP	Hirayama, *et al.*, "Structure and conformation of a novel inhibitor of angiotensin I converting enzyme – a tripeptide containing phosphonic acid," Int. J. Pept. Protein Res. 38: 20-24 (1991)
BQ	Hunston, *et al.*, "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)

EXAMINER:	DATE CONSIDERED: 8/2/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) COPY OF PAPERS ORIGINALLY FILED
	BR	Keenan, *et al.*, "Pathology Reevaluation of the Kociba *et al.* (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment," J. Tox. Envir. Health 34: 279-296 (1991)
	BS	Kelley, *et al.*, "[[(Guaninylalkl) phosphinico] methyl] phosphonic Acids. Multisubstrate Analogue inhibitors o Human Erythrocyte Purine Nucleoside Phosphorylase," J. Med. Chem. 38: 1005-1014 (1995)
	BT	Khamnei and Torrence, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem. 39: 4109-4115 (1996)
	BU	Kryuchkov, *et al.*, Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	BV	Lok, *et al.*, "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 (1984)
	BW	Lu *et al.*, "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with *O,O*-Dialkyl Phosphonates Synthesis, 726-727 (1987)
	BX	McGuigan, *et al.*, "Kinase Bypass: A new strategy for Anti-Hiv Drug Design," Bioorganic & Medicinal Chemistry Letters, 3(6): 1207-1210 (1993)
	BY	Meier, *et al.*, "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2'3'-didehydrothymidine (d4t)," Bioorganic & Medicinal Chemistry Letters, 7(2): 99-104 (1997)
	BZ	Meijer, *et al.*,"Covalent and Noncovalent Protein Binding of Drugs: Implications for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," Pharm. Res. 6: 105-118 (1989)
	CA	Melvin, "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," Tetrahedron Lett., 22(35): 3375-3376 (1981)
	CB	Meyer, *et al.*, "2"-*O*'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prorugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979)

EXAMINER:	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OTHER DOCUME... (Including Author, Title, Date, ...nt Pages, etc.)		COPY OF PAPER ORIGINALLY FILE
	CC	Mitchell, *et al.*, "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methlphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin Trans. 1 1992
	CD	Mitsunobu, "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformatio of Natural Products," Synthesis, 1-28 (1981)
	CE	Moore, *et al.*, "Comparison of Mutagenicity results for Nine Coumpounds exaluated at the *hgprt* Locus in the Standard and Suspension CHO Assays," Mutagenisis 6: 77-85 (1991)
	XE	Murray, *et al.*, "Cytochrome P450 Expression is a common Molecular Event in Soft Tissue Sarcomas," J. Pathology, 171, 49-52 (1993)
	XF	Murray, *et al.*, "Cytochrome P450 CYP3A in human renal cell cancer," British J. Cancer, 79, 1836-1842 (1999)
	CF	Neidlein, *et al.*, "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)
	CG	Nifantyev, *et al.*,"Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phosphorus, Sulfu Silicon and Related Elements 113: 1-13 (1996)
	XG	Ogg, *et al.*, *Xenobiotica* 29, 269-279 (1999)
	CH	Ohashi, *et al.*, "Synthesis of Phosphonosphingoglycolipid found in Marine Snail Turbo Comutus," Tetrahedron Lett., 29(10): 1189-1192 (1988)
	CI	Petrakis, *et al.*, Palladium-Catalyzed Substitutions of Triflates Derived from Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-(Diethoxyphosphinyl) phenylalanines and Diethyl Arylphosphonates," J. Am. Chem. Soc., 109: 2831-2833 (1987)
	CJ	Redmore, "Phosphorus Derivatives of Nitrogen Heterocycles," J. Org. Chem., 35(12): 4114-4117 (1970)

EXAMINER:	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

		OTHER DOCUME: (Including Author, Title, Date, nt Pages, etc.) COPY OF PAPERS ORIGINALLY FILED
	CK	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (supp) s24 (1993)
	CL	Shih, *et al.*, "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides, Bull. Inst. Chem. Acad. Sin, 41: 9-16 (1994)
		Turner, "A General Appproach to the Synthesis of 1,6-,1,7-, and1,8-Naphthyridines," J. Org. Chem. 55(15) (1990)
	XH	Venook, A.P, "Treatment of Heptacellular Carcinoma: Too Many Options?" *J. Clin. Oncol.* 12, 1323-1334 (1994)
	CN	Vo-Quang, *et al.*, "(1-Amino-2-propenyl) Phosphonic Acid, an Inhibitor of Alanine Racemase and D-Alanine:D-Alanine Ligase.," J. Med. Chem. 29(4): 579-581 (1986)
	CO	Wagner, *et al.*, "Direct Conversion of Tetrahydropyranylated Alcohols to the corresponding Bromides," Tetrahedron Letters 30(5): 557-558 (1989)
	CP	Wallace, *et al.*, "Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme," J. Med. Chem. 41: 1513-1523 (1998)
	CQ	Walsh, *et al.*, "The Structures of Grantianine and Sceleratine," J. Am. Chem. Soc., 78: 4455-4458 (1956)
	XI	Watkins, *et al.*, Pharmacogenetics 4, 171-184 (1994)
	CR	Weibel, *et al.*, "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-oxo-9H-Purin-9-yl)Methyl]-Phenyl]Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine Nucleoside Phosphorylase, o the Antiretroviral Activities of 2', 3'- Dideoxyinosine Combined to Ribavirin in Mice," Biochem. Pharmacol. 48(2):245-252 (1994)
	CS	Wileman, *et al.*, "Receptor – mediated endocytosis," Biochem. J. 232: 1-14 (1985)

EXAMINER:	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OTHER DOCUME... (Including Author, Title, Date, ...ent Pages, etc.)		
	XJ	Yu, *et al.*, "In Vivo Modulation of alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," *J. Pharm. Exp. Ther.* 288, 928-937 (1999)
	CT	Zon, "Cyclophosphamide Analogues," Progress in Med Chem. 19: 1205-1246 (1982)
	CU	Predvoditelev D. , *et al.*, "Glycero-2-hydroxymethylene phosphates" Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977)
	CV	Predvoditelev, D. *et al.*, "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981)
	CW	Hillers, *et al.*, "Analogs of pyrimidinemono- and polynucleotides. VI. Phosphates of 1-(1,4-dihydroxy-2-pentyl) thymine and 1-(1,3-dihydroxy-2-propyl) uracil" 89 (17): 1-264 (1978)
	CX	Farquhar, *et al.*, "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorinan –2-y]-2'-deoxy-5-fluorouridine: a membrane permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" Journal of Medicinal Chemistry 38:488-495 (1995)

COPY OF PAPERS ORIGINALLY FILED

EXAMINER:	DATE CONSIDERED: 8/21/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant